4-[4-[[2-(2-cyanoethylamino)acetyl]amino]phenyl]-N-(2,6-dichlorophenyl)piperidine-1-carboxamide | 1092066-50-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-[4-[[2-(2-cyanoethylamino)acetyl]amino]phenyl]-N-(2,6-dichlorophenyl)piperidine-1-carboxamide
• CAS: 1092066-50-6
• 化学式: C₂₃H₂₅Cl₂N₅O₂
• 分子量: 474.39
• InChiKey: RWKDKTANUAXCIF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  97.3
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST
  申请人：Linders Joannes Theodorus Maria

  公开号：US20110112111A1

  公开（公告）日：2011-05-12

  The present invention relates to combinations of a DGAT inhibitor and a peroxisome proliferator-activator receptor (PPAR) agonist or a prodrug thereof. The invention further relates to methods for preparing such combinations, pharmaceutical compositions comprising said combinations as well as the use as a medicament of said combinations. The present invention also relates to novel DGAT inhibitors. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicament of said compounds.

  本发明涉及一种DGAT抑制剂和过氧化物酶体增殖激活受体（PPAR）激动剂或其前药的组合物。本发明还涉及制备这种组合物的方法，以及包含该组合物的制药组合物和该组合物作为药物的用途。本发明还涉及新型的DGAT抑制剂。本发明还涉及制备这种化合物的方法，以及包含该化合物的制药组合物和该化合物作为药物的用途。
• Drug combinations comprising a DGAT inhibitor and a PPAR-agonist
  申请人：Janssen Pharmaceutica, N.V.

  公开号：EP2296659B1

  公开（公告）日：2016-12-21
• PIPERIDINE/PIPERAZINE DERIVATIVES
  申请人：Bongartz Jean-Pierre Andre Marc

  公开号：US20100190789A1

  公开（公告）日：2010-07-29

  The invention relates to a DGAT inhibitor of formula (I): including any stereochemically isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents —C(═O)—; —O—C(═O)—; C(═O)—C(═O)—; —NR x —C(═O)—; —Z 1 —C(O)—; —Z 1 —NR x —C(═O)—; —C(═O)—Z 1 —; —NR x —C(═O)—Z 1 —; —S(═O)p-; —C(═S)—; —NR x —C(═S)—; —Z 1 —C(═S)—; —Z 1 —NR x —C(═S)—; —C(═S)—Z1-; NR x —C(═S)—Z—; Y represents NR x —C(= 0 )-Z 2 —; —NR x —C(= 0 )-Z 2 —NR y —; —NR x —C(= 0 )-Z 2 —NR y —C(= 0 )—; —NR x —C(= 0 )-Z 2 —NR y —C(= 0 )-; O—; —NR x —C(= 0 )-Z 2 - 0 -; —NR x —C(= 0 )-Z 2 - 0 -C(= 0 )-; —NR x —C(= 0 )-Z 2 —C(= 0 )-; —NR x —C(= 0 )-Z 2 —C(= 0 )-; —NR x —C(= 0 )- 0 -Z 2 —C(= 0 )-; —NR x —C(= 0 )- 0 -Z 2 —C(= 0 )- 0 -; —NR x —C(═O)—O—Z 2 —O—C(═O)—; —NR x —C(═O)—Z 2 —C(═O)—NR y —; —NR x —C(═O)—Z 2 —NR y —C(= 0 )-NR y —; —C(═O)—Z 2 —; —C(═O)—Z 2 —O—; —C(= 0 )-NR x —Z 2 —; —C(= 0 )-NR x —Z 2 - 0 -; —C(= 0 )-NR x —Z 2 —C(= 0 )- 0 -; —C(= 0 )-NR x —Z 2 - 0 -C(= 0 )-; —C(= 0 )-NR x —Z 2 —NR y —; —C(= 0 )—NR x —Z 2 —NR y —C(= 0 )-; —C(= 0 )-NR x —Z 2 —NR y —C(= 0 )- 0 -; R 1 represents C 1-12 alkyl optionally substituted with cyano, C 1-4 alkyloxy, C 1-4 alkyl-oxyC 1-4 alkyloxy, C 3-6 Cycloalkyl or aryl; C 2-6 alkenyl; C 2-6 alkynyl; C 3-6 cycloalkyl; adamantanyl; aryl 1 ; aryl 1 C 1-6 alkyl; Het 1 ; or Het 1 C 1-6 alkyl; provided that when Y represents —NR x —C(═O)—Z 2 —; —NR x —C(= 0 )-Z 2 —NR y ; —NR x —C(═O)—Z 2 —C(═O)—NR y —; —C(═O)—Z 2 —; —NR x —C(= 0 )-Z 2 —NR y —C(= 0 )—NR y —; —C(═O)—NR—Z 2 —; —C(═O)—NR—O—Z 2 —; or —C(= 0 )-NR x —Z 2 —NR y —; then R 1 may also represent hydrogen; R 2 represents hydrogen, C 1-12 alkyl, C 2-6 alkenyl or R 3 ; provided that if X represents —O—C(═O)—; the R 2 O represents R 3 ; and provided that (A) is excluded; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds.
• US8981094B2
  申请人：——

  公开号：US8981094B2

  公开（公告）日：2015-03-17
• US9107946B2
  申请人：——

  公开号：US9107946B2

  公开（公告）日：2015-08-18